This trial is testing a new drug, YY-15293, to see if it is safe and effective in treating patients with advanced solid tumors (cancer that has spread) with a KRAS G12C mutation.
- Advanced Solid Tumors
1 Primary · 3 Secondary · Reporting Duration: Throughout the study for approximately 2 years
Awards & Highlights
1 Treatment Group
1 of 1
55 Total Participants · 1 Treatment Group
Primary Treatment: YL-15293 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still openings for enrolment in this trial?
"Confirmed. Clinicaltrials.gov reports that this medical experiment was initially announced on November 9th 2021 and has been most recently updated on the 11th of the same month, indicating it is actively seeking participants." - Anonymous Online Contributor
What is the current intake quota for this clinical trial?
"The sponsor, Shanghai YingLi Pharmaceutical Co. Ltd., must enroll 55 qualified participants across multiple sites; including Oncology Consultants in Houston and Innovative Clinical Research Institute in Whittier." - Anonymous Online Contributor